Metafort-G 853 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 3 mg and Metformin 850 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. This dual-action formulation offers complementary mechanisms to effectively lower blood sugar in patients inadequately controlled by diet and exercise alone. Metafort-G 853 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose regularly to adjust dosage appropriately and minimize risks of hypoglycemia, particularly due to the sulfonylurea component. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or conditions predisposing to lactic acidosis. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rare instances of lactic acidosis. Patient adherence and periodic evaluation of renal function are essential to ensure safety and therapeutic efficacy. This combination tablet provides a convenient and effective option for improving glycemic control in type 2 diabetes patients.

Dosage & How to Use